Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α

24 Feb 2014

Abstract excerpt

The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24569456
DOI: 10.1172/jci69927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110αPMID 24569456Read ↗

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.Semantic proximity Read ↗

Targeting RAS Signaling Pathways in Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesisSemantic proximity Read ↗

Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderSemantic proximity Read ↗

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.Semantic proximity Read ↗

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.Semantic proximity Read ↗

Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.Semantic proximity Read ↗

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem CellsSemantic proximity Read ↗

Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.Semantic proximity Read ↗

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.Semantic proximity Read ↗

STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.Semantic proximity Read ↗

Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.